Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Formosa Pharmaceuticals Licenses APP13007 Eye Drops to Samil Pharma for South Korea Market

Fineline Cube Feb 10, 2026
Company Deals

Nanjing Hanxin Licenses AC02 ACTH Analogue to Amphastar for $151 Million US/Canada Deal

Fineline Cube Feb 10, 2026
Company Deals

Chia Tai Fenghai Licenses FHND5032 miR-124 Inducer to Formation Bio for $500 Million

Fineline Cube Feb 10, 2026
Company Deals

Henlius Biotech Secures Global Rights to U-mab’s IL-1RAP Antibody in Licensing Deal

Fineline Cube Feb 10, 2026
Company Deals

Zhongsheng Pharma Licenses RAY1225 GLP-1/GIP Dual Agonist to Qilu Pharma for $144 Million

Fineline Cube Feb 10, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026
Company Deals Drug

Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage

Fineline Cube Feb 10, 2026
Company Drug

Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market

Fineline Cube Feb 9, 2026
Company Deals

Akeso Receives First $300M Installment from Summit for Bispecific Antibody Ivonescimab

Fineline Cube Jan 29, 2023

Akeso Inc. (HKG: 9926) has announced receiving the first installment of USD 300 million as...

Policy / Regulatory

NMPA Proposes Emergency Use Management Measures for Medical Devices

Fineline Cube Jan 29, 2023

The National Medical Products Administration (NMPA) has released the “Medical Device Emergency Use Management Measures”...

Company Drug

InnoCare’s Gunagratinib Shows Promising Data in Cholangiocarcinoma at ASCO-GI 2023

Fineline Cube Jan 29, 2023

Beijing InnoCare Pharma Tech Co. (HKG: 9969), a China-based biotech specializing in cancer and autoimmune...

Company Drug

Exegenesis Bio Gains FDA Approval for Gene Therapy EXG102-031 in Wet AMD

Fineline Cube Jan 29, 2023

Hangzhou-based clinical stage gene therapy firm Exegenesis Bio has announced receiving approval from the US...

Company Drug

Simcere’s Cosela Receives First Prescription in China for CDK4/6 Inhibition

Fineline Cube Jan 29, 2023

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the issuance of the first prescription for...

Policy / Regulatory

China Updates Export Controls on Technologies, Adds Gene Editing to List

Fineline Cube Jan 29, 2023

The Ministry of Finance (MOF) has released an updated notification regarding technologies banned and restricted...

Company Drug

Novartis’ Kisqali Receives NMPA Approval for Premenopausal Breast Cancer

Fineline Cube Jan 28, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced receiving marketing approval from the National Medical...

Company Drug

Fosun Pharma’s Comirnaty Bivalent Vaccine Approved in Macau for Booster Shots

Fineline Cube Jan 28, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its Comirnaty...

Company Drug

HuidaGene Receives FDA IND Approval for Ophthalmology Gene Therapy HG004

Fineline Cube Jan 28, 2023

China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced receiving Investigational New Drug (IND) approval from...

Company Deals

Yinghe Brain Science Raises RMB 100 Million in Angel Financing Round

Fineline Cube Jan 28, 2023

Shenzhen Yinghe Brain Science Co., Ltd, a China-based neurotechnology firm, has reportedly raised over RMB...

Company Deals

HutchMed Signs Licensing Deal with Takeda for Global Fruquintinib Development

Fineline Cube Jan 28, 2023

Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced a licensing deal with Japanese...

Company Deals

Tianjin-Based Protein T Raises RMB 100 Million in Series A Financing

Fineline Cube Jan 28, 2023

Tianjin-based biotech Protein T, focused on multi-omics research, has reportedly raised close to RMB 100...

Company Drug

Ascletis Receives IND Approval for ASC10 in Monkeypox Treatment

Fineline Cube Jan 28, 2023

China-based Ascletis Pharma Inc. (HKG: 1672) has announced receiving Investigational New Drug (IND) approval from...

Company Drug

Legend Biotech’s Carvykti Meets Primary Endpoint in CARTITUDE-4 Phase III Study

Fineline Cube Jan 28, 2023

Legend Biotech (NASDAQ: LEGN) has released positive data from the CARTITUDE-4 Phase III study, evaluating...

Company Drug

CSPC’s Octreotide Long-Acting Injection Approved for Acromegaly Clinical Study

Fineline Cube Jan 20, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving approval from the National Medical...

Company Drug

BeiGene’s Brukinsa Approved by FDA for Chronic Lymphocytic Leukemia

Fineline Cube Jan 20, 2023

China-based BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced that the US FDA has...

Company Deals

Dartsbio Pharmaceuticals Secures RMB 100 Million in Series B Financing

Fineline Cube Jan 20, 2023

Guangdong-based antibody drug developer Dartsbio Pharmaceuticals has reportedly raised over RMB 100 million in a...

Company Drug

CNBG-Virogin’s Omicron-Targeted mRNA Vaccine Approved for Clinical Trials

Fineline Cube Jan 20, 2023

CNBG-Virogin Biotech (Shanghai) Co., Ltd has announced obtaining clinical trial approval from the National Medical...

Company Drug

Hepagene’s FXR Agonist HPG1860 Shows Positive Phase IIa Data in NASH Study

Fineline Cube Jan 20, 2023

China-based liver disease specialist Hepagene Therapeutics (HK) Limited has revealed positive data from the Phase...

Company Deals

Ascentage Pharma Raises HKD 550 Million in Secondary Offering for Pipeline Expansion

Fineline Cube Jan 19, 2023

Suzhou-based Ascentage Pharma (HKG: 6855) is set to conduct a secondary offering of 22.5 million...

Posts pagination

1 … 526 527 528 … 622

Recent updates

  • Formosa Pharmaceuticals Licenses APP13007 Eye Drops to Samil Pharma for South Korea Market
  • Nanjing Hanxin Licenses AC02 ACTH Analogue to Amphastar for $151 Million US/Canada Deal
  • Chia Tai Fenghai Licenses FHND5032 miR-124 Inducer to Formation Bio for $500 Million
  • Henlius Biotech Secures Global Rights to U-mab’s IL-1RAP Antibody in Licensing Deal
  • Zhongsheng Pharma Licenses RAY1225 GLP-1/GIP Dual Agonist to Qilu Pharma for $144 Million
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Formosa Pharmaceuticals Licenses APP13007 Eye Drops to Samil Pharma for South Korea Market

Company Deals

Nanjing Hanxin Licenses AC02 ACTH Analogue to Amphastar for $151 Million US/Canada Deal

Company Deals

Chia Tai Fenghai Licenses FHND5032 miR-124 Inducer to Formation Bio for $500 Million

Company Deals

Henlius Biotech Secures Global Rights to U-mab’s IL-1RAP Antibody in Licensing Deal

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.